Assessing Novo Nordisk’s Long-Term Prospects
Assessing Novo Nordisk’s Long-Term Prospects
Novo Nordisk (NYSE: NVO) has proven to be a stellar performer, outpacing the market significantly over the past decade. With a remarkable 10-year return of 527%, dwarfing the S&P 500‘s gain of 182%, the company has certainly caught investors’ attention. While its recent surge in 2022 propelled the stock to new heights, driven largely by ...
